- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06272097
Postoperative Wounds With Delayed Healing Risk of Clinical Trial Registration
Optimization Program for the Care Management of Wounds With Delayed Healing Risk After Hip Arthroplasty Based on TIME CDST Tool: a Randomized Controlled Trial Protocol
Study Overview
Status
Conditions
Detailed Description
- Research Background and Objectives Orthopedic surgical wounds present more complex healing challenges compared to other surgical wounds. Hip arthroplasty is the most common type of orthopedic surgery. Due to surgical complexity or patient-specific factors, this procedure is particularly prone to surgical complications such as surgical site infection, wound dehiscence, tissue necrosis, and hematoma, thereby increasing the risk of delayed wound healing postoperatively.To improve the healing outcomes of postoperative wounds with delayed healing, optimizing nursing management protocols is crucial. This study aims to optimize nursing management for wounds with delayed healing risk after hip arthroplasty using the TIME CDST tool and validate its effectiveness.
Research Methods Study Design: This study employed a randomized controlled trial design, randomly assigning participants to an experimental group and a control group, which received different nursing management protocols.
Sample Size: A total of 492 patients are expected to be included, with 246 in the experimental group and 246 in the control group.
Intervention Measures: Patients in the experimental group will receive nursing management based on the TIME CDST tool, while those in the control group will receive conventional nursing management.
Evaluation Indicators: The primary outcome measure is wound healing time. Secondary outcome measures include the number of cases with wound healing, wound area reduction rate, ASEPSIS wound scoring system, Stone-Brock Scar Scoring Scale (SBSES), Visual Analog Scale (VAS), patient comfort score, patient satisfaction score, albumin levels, dressing change frequency, and medical costs.Clinical adverse events will be recorded for safety assessment.
Data collection and analysis: Data will be collected through questionnaire surveys, observation records, statistical analysis, and comparative analysis.
Study process Screening and grouping: Patients meeting the inclusion criteria will be screened and randomly assigned to the experimental group and control group.
Intervention Implementation: The experimental group will receive a nursing management plan based on the TIME CDST tool, while the control group will receive routine nursing management.
Follow-up and Evaluation: Regularly assess patients' wound conditions, record healing status, and collect patient satisfaction data.
Data Analysis: Analyze the collected data and compare differences between the experimental group and the control group in terms of various assessment indicators.
Result Interpretation and Report Writing: Based on the data analysis results, draw conclusions and write the research report.
Expected Results
Through the implementation of this study, the researchers expect to draw the following conclusions:
The nursing management plan based on the TIME CDST tool can significantly shorten the wound healing time after hip replacement surgery.
This plan can improve the wound healing rate after hip replacement surgery. This plan can enhance patient satisfaction with nursing services. This plan has practical application and promotion value in clinical practice.
- Significance and Value of the Study This study holds significant importance and value for optimizing nursing management of wounds with delayed healing risk. Through scientific experimental design and rigorous data analysis, researchers can provide effective nursing management strategies for clinical practice, thereby improving patient outcomes and quality of life. Additionally, the findings of this study can serve as a reference and inspiration for other similar studies, contributing to the advancement and development of the nursing management field.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Danni Feng
- Phone Number: 0086-13476022370
- Email: 992911819@qq.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age ≥18 years;
- First-time recipient of unilateral total HA or hemiarthroplasty;
- Postoperative wound healing delay risk, defined as epithelialization <50% at 2 weeks postoperatively (quantified using a standardized manual planar measurement method: on day 14 postoperatively, a (quantified using a standardized manual planar measurement method: on day 14 postoperatively, a standardized transparent grid membrane with 1mm² graduations is placed vertically over the wound, and the wound perimeter and epithelialization boundary are marked with a surgical marker. boundary are marked with a surgical marker pen; the epithelialized area is defined as pink, non-exudative tissue completely covering the dermis); Normal cognitive and communication abilities;
- Ability to comply with relevant nursing measures;
- Voluntary participation in this trial
- Voluntary participation in this trial and signed informed consent form.
Exclusion Criteria:
- Active infection at the surgical site prior to initial hip surgery; Deep surgical site infection (SSI) or periprosthetic joint infection (PJI) diagnosed or strongly suspected at screening. diagnosed or strongly suspected at screening (based on clinical symptoms, imaging, or aspiration results according to the MSIS/EBJIS criteria);
- Complete wound dehiscence (>2 cm) or exposure of the prosthesis/bone cement, requiring emergency revision surgery;
- Severe vascular insufficiency (ABI <0.5 cm);
- Severe acute and chronic chronic disease (ABI <0.5 cm) insufficiency (ABI <0.6, severe limb ischemia);
- Uncontrolled systemic conditions severely impairing healing potential: severe malnutrition or obesity (BMI≥ 40 kg/m² or≤ 16 kg/m² or serum albumin <2.5 g/dL); Uncontrolled diabetes (HbA1c >9% in the past 3 months); severe heart failure (NYHA IV); severe liver dysfunction (Child-Pugh C); severe renal failure requiring dialysis; active malignant tumors; immunosuppressive therapy (high-dose corticosteroids >10 mg prednisolone); and dose corticosteroids >10 mg prednisone equivalent/day, biologics, or immunosuppressive agents following transplantation).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change.
|
Based on the TIME CDST tool led by wound specialist nurses, which includes the following five areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment; E. Evaluate and reassess the treatment and wound management outcomes; Give patients health education on wound care management.
|
|
Other: Control group
The control group receives a routine wound care program of wound cleaning and dressing changes at each dressing change.
|
A routine wound care program of wound cleaning and dressing changes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound healing time
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Wound healing time will be assessed as the primary outcome indicator.
Complete epithelialization of the wound is considered as wound healing and the time taken from enrollment to complete wound healing will be recorded for both groups.
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of cases with wound healing
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
The number of cases in which the wound will be completely epithelialized (defined as pink, non-exudative tissue completely covered by epithelium) during the period from enrollment to the endpoint
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
The rate of wound area reduction
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
The rate of wound area reduction will be calculated through the following expression: (original wound area - present wound area)/original wound area × 100%.
The accuracy of wound area measurements can be improved by placing a uniform wound measuring tape on one side of the wound and taking a picture of the wound area using image processing and analysis with Image J software (National Institutes of Health, Bethesda, MD).
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
ASEPSIS wound scoring system
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
The ASEPSIS wound scoring system will be used to assess surgical wound infection and healing.
This evaluation criteria primarily evaluates multiple aspects including wound characteristics, antibiotic use, wound drainage, local debridement, bacterial culture, hospital stay, and home care of the wound.
A higher score indicates more severe wound infection.
(Total score: 0 to 10 indicates satisfactory healing; 11 to 20 indicates poor healing; 21 to 30 indicates mild wound infection; 31 to 40 indicates moderate wound infection; and greater than 40 indicates severe wound infection.)
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
Stony Brook Scar Evaluation Scale (SBSES)
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
The Stony Brook Scar Evaluation Scale (SBSES) will be measured the aesthetic outcome of postoperative wounds, including five criteria: width, height, color, suture line, and overall appearance.
Each criterion is scored as 0 or 1, with a total score ranging from 0 (worst) to 5 (best)
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
The pain intensity
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
The pain intensity is evaluated using the visual analogue scale (VAS).
In the absence of pain, a score of 0 represents a painless state; a score of 1 to 3 represents mild pain; a score of 4 to 6 represents moderate pain; and a score of 7 to 10 represents severe pain.
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
Patient comfort score
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Use a self-made nursing comfort questionnaire to evaluate the patient's nursing comfort.
The questionnaire was conducted on a 10 point scale, with scores>9 indicating extreme comfort, 8-9 indicating relative comfort, 6-7 indicating basic comfort, and<6 indicating discomfort.
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
Patient satisfaction score
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Use a self-made nursing satisfaction questionnaire to evaluate the patient's nursing satisfaction.
Both questionnaires were conducted on a 10 point scale, with scores>9 indicating very satisfied, 8-9 indicating relative satisfaction, 6-7 indicating basic satisfaction, and<6 indicating dissatisfaction.
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
Albumin levels
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Albumin levels
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
The frequency of dressing changes
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
The frequency of dressing changes
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
|
Medical expenses
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Medical cost expenditure
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety evaluation
Time Frame: The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Clinical events were recorded, including reasons for non-healing (infection, hematoma, abscess, wound dehiscence, rejection reaction), antibiotic treatment, readmission, reoperation, amputation, and death.
|
The time frame is from the date of intervention to the date of complete wound healing or the outcome endpoint, whichever comes first, with an assessment period of 6 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Danni Feng, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201328
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound Heal
-
Peking University Third HospitalRecruitingWound Heal | Wound Healing DelayedChina
-
University of Southern California3MWithdrawnWound Heal | Wound Dehiscence
-
Minia UniversityNot yet recruiting
-
ConvaTec Inc.Charleston Wound Care CentreCompleted
-
Melaka Manipal Medical CollegeCompleted
-
Basaksehir Cam & Sakura Şehir HospitalIstanbul Kent UniversityEnrolling by invitation
-
RWTH Aachen UniversityWithdrawn
-
Cook Biotech IncorporatedRecruitingWounds and Injuries | Surgical Wound | Wound Heal | WoundUnited Kingdom
-
Shanghai Ninth People's Hospital Affiliated to...Recruiting
-
Salma NabilRecruiting
Clinical Trials on A routine wound care program
-
Alexandria UniversityRecruiting
-
NYU Langone HealthTerminated
-
National Taipei University of Nursing and Health...Completed
-
Ministry of Science and Technology, TaiwanCompletedCognitive Change | Education
-
University Hospital, BrestRecruitingAddiction, Substance | Addiction, AlcoholFrance
-
King Abdullah University HospitalJordan University of Science and TechnologyCompleted
-
China Medical University HospitalRecruiting
-
Cyprus Aydin UniversityRecruitingStress | Hemodialysis | Sleep Quality | SymptomCyprus
-
Emine ŞAHİNRecruitingShortness of BreathTurkey (Türkiye)
-
Biobizkaia Health Research InstituteNot yet recruiting